Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities:
Net income (loss)	$ (3,261,618)	$ (3,363,597)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	312,500
Interest expenses	322,144
Impairment loss	624,289
Stock based compensation	690,875	2,441,926
Changes in operating assets and liabilities:
Prepaid expenses and other receivable	170,256	(37,706)
Accounts payable and accrued expenses	629,645	122,876
Due to related party		(33,902)
Net Cash used in Operating Activities	(511,909)	(870,403)
Cash Flows from Investing Activities:
Investment in 369 Hemp	(429,289)
Investment in Metabiogenix (US)	(50,000)	(160,000)
Prepayments for acquisition - related party		(145,000)
Net Cash used in Investing Activities	(479,289)	(305,000)
Cash Flows from Financing Activities:
Proceeds from convertible notes	250,000
Proceeds from stock subscriptions for shares to be issued	401,000	576,000
Proceeds from issuance of common stock and warrants	121,000	600,000
Net Cash provided by Financing Activities	772,000	1,176,000
Net change in cash	(219,198)	597
Cash, beginning of period	226,231	232,850
Cash, end of period	(0)	226,231
Supplemental Cash Flow Information
Cash paid for interest
Cash paid for taxes
Non-Cash Investing and Financing Activities:
Common stock and warrants issued from shares to be issued	$ 576,000